Correlation Between Ikena Oncology and Cyteir Therapeutics
Can any of the company-specific risk be diversified away by investing in both Ikena Oncology and Cyteir Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ikena Oncology and Cyteir Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ikena Oncology and Cyteir Therapeutics, you can compare the effects of market volatilities on Ikena Oncology and Cyteir Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ikena Oncology with a short position of Cyteir Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ikena Oncology and Cyteir Therapeutics.
Diversification Opportunities for Ikena Oncology and Cyteir Therapeutics
-0.24 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Ikena and Cyteir is -0.24. Overlapping area represents the amount of risk that can be diversified away by holding Ikena Oncology and Cyteir Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cyteir Therapeutics and Ikena Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ikena Oncology are associated (or correlated) with Cyteir Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cyteir Therapeutics has no effect on the direction of Ikena Oncology i.e., Ikena Oncology and Cyteir Therapeutics go up and down completely randomly.
Pair Corralation between Ikena Oncology and Cyteir Therapeutics
If you would invest 169.00 in Ikena Oncology on September 13, 2024 and sell it today you would earn a total of 1.00 from holding Ikena Oncology or generate 0.59% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 1.59% |
Values | Daily Returns |
Ikena Oncology vs. Cyteir Therapeutics
Performance |
Timeline |
Ikena Oncology |
Cyteir Therapeutics |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Ikena Oncology and Cyteir Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Ikena Oncology and Cyteir Therapeutics
The main advantage of trading using opposite Ikena Oncology and Cyteir Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ikena Oncology position performs unexpectedly, Cyteir Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyteir Therapeutics will offset losses from the drop in Cyteir Therapeutics' long position.Ikena Oncology vs. Puma Biotechnology | Ikena Oncology vs. Iovance Biotherapeutics | Ikena Oncology vs. Sarepta Therapeutics | Ikena Oncology vs. Day One Biopharmaceuticals |
Cyteir Therapeutics vs. Nuvation Bio | Cyteir Therapeutics vs. Foghorn Therapeutics | Cyteir Therapeutics vs. C4 Therapeutics | Cyteir Therapeutics vs. Prelude Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |